CMS maintains VNS Therapy for DRE at Level 5 APC for 2025; LivaNova sees no business impact

LivaNova PLC

CMS announced on Nov 1, 2024 it will keep VNS Therapy for drug-resistant epilepsy at Level 5 Neurostimulator APC under the 2025 Medicare Hospital Outpatient PPS.
LivaNova says it is disappointed by the decision but does not expect any impact on its business.
The company plans to continue pursuing improved reimbursement for VNS Therapy for DRE.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.